A Phase I Multiple Ascending Dose (MAD) Study of RO5458640, a Humanized Monoclonal Antibody Against the TNF-like Weak Inducer of Apoptosis (TWEAK) Ligand, in Patients with Advanced Solid Tumors

Cancer type: Solide tumores

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, NF-kappa-B pathway, monoclonal antibody, first in humans, Fn14 expression

Status: Completed

Link to